Aurobindo Pharma traded at 1,164.15 this Monday February 2nd, decreasing 48.15 or 3.97 percent since the previous trading session. Looking back, over the last four weeks, Aurobindo Pharma lost 3.58 percent. Over the last 12 months, its price rose by 3.30 percent. Looking ahead, we forecast Aurobindo Pharma to be priced at 1,189.51 by the end of this quarter and at 1,123.67 in one year, according to Trading Economics global macro models projections and analysts expectations.
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.